(Reuters) – A new type of dye for magnetic resonance imaging procedures may let doctors diagnose lung cancer at much earlier stages than is currently possible, researchers found.
In animal studies, the protein-based contrast agent called hProCA32.Collagen2, under development by InLighta BioSciences, allowed for identification of lung tumors and metastases as small as 1 millimeter, according to a report in Science Advances.
Beyond diagnosis, the findings may have important implications for personalized cancer treatment, the researchers said.
Read more at the source
